收费全文 | 2354215篇 |
免费 | 195657篇 |
国内免费 | 4094篇 |
耳鼻咽喉 | 34200篇 |
儿科学 | 72410篇 |
妇产科学 | 62829篇 |
基础医学 | 331705篇 |
口腔科学 | 67399篇 |
临床医学 | 213378篇 |
内科学 | 462334篇 |
皮肤病学 | 47864篇 |
神经病学 | 198997篇 |
特种医学 | 95748篇 |
外国民族医学 | 886篇 |
外科学 | 359059篇 |
综合类 | 56095篇 |
一般理论 | 976篇 |
预防医学 | 188596篇 |
眼科学 | 55253篇 |
药学 | 176796篇 |
4篇 | |
中国医学 | 4257篇 |
肿瘤学 | 125180篇 |
2018年 | 23885篇 |
2016年 | 20303篇 |
2015年 | 23014篇 |
2014年 | 33389篇 |
2013年 | 50680篇 |
2012年 | 68645篇 |
2011年 | 72171篇 |
2010年 | 42344篇 |
2009年 | 40737篇 |
2008年 | 68656篇 |
2007年 | 72998篇 |
2006年 | 73893篇 |
2005年 | 71927篇 |
2004年 | 69221篇 |
2003年 | 66872篇 |
2002年 | 66102篇 |
2001年 | 112283篇 |
2000年 | 116227篇 |
1999年 | 97686篇 |
1998年 | 26154篇 |
1997年 | 23778篇 |
1996年 | 23734篇 |
1995年 | 24450篇 |
1994年 | 23021篇 |
1993年 | 21430篇 |
1992年 | 79263篇 |
1991年 | 76372篇 |
1990年 | 73518篇 |
1989年 | 70782篇 |
1988年 | 65776篇 |
1987年 | 64749篇 |
1986年 | 61288篇 |
1985年 | 58365篇 |
1984年 | 44146篇 |
1983年 | 37541篇 |
1982年 | 22794篇 |
1981年 | 20226篇 |
1980年 | 18932篇 |
1979年 | 41222篇 |
1978年 | 28904篇 |
1977年 | 24225篇 |
1976年 | 22683篇 |
1975年 | 23855篇 |
1974年 | 29534篇 |
1973年 | 27962篇 |
1972年 | 26166篇 |
1971年 | 24110篇 |
1970年 | 22704篇 |
1969年 | 21043篇 |
1968年 | 19093篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献